General Information of Drug (ID: DMOJ8QR)

Drug Name
PMID23312943C21 Drug Info
Synonyms GTPL8135; BDBM50425862
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
71553154
TTD Drug ID
DMOJ8QR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [2]
Fostamatinib disodium DM3274D Thrombocytopenia 3B64 Phase 3 [3]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [4]
TAK-659 DMJH3U0 Diffuse large B-cell lymphoma 2A81 Phase 2 [5]
GS-9876 DM9Q2B6 Cutaneous lupus erythematosus EB5Z Phase 2 [6]
GS-9973 DMKWCTR Acute myeloid leukaemia 2A60 Phase 2 [7]
Cevidoplenib DM9QU5G Rheumatoid arthritis FA20 Phase 2 [8]
HM43239 DMV1SDA Acute myeloid leukaemia 2A60 Phase 1/2 [9]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [10]
SKI-O-703 DMTSKXR Rheumatoid arthritis FA20 Phase 1 [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BDBM50011553 DMHNYQU N. A. N. A. Patented [11]
6-Phenylquinazolin-4-amine DMV5XR7 N. A. N. A. Patented [11]
BDBM50011552 DMW5SD6 N. A. N. A. Patented [11]
PMID24673130C26 DM2HVU8 Discovery agent N.A. Investigative [12]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MEK kinase kinase 4 (MAP4K4) TT6NI13 M4K4_HUMAN Inhibitor [1]
Tyrosine-protein kinase SYK (SYK) TTOU65C KSYK_HUMAN Inhibitor [1]

References

1 Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Company report (Portola Pharmaceuticals)
5 J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
8 A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
9 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
10 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
11 Aminoquinazoline and pyridopyrimidine derivatives. US9592235.
12 Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization. J Med Chem. 2014 Apr 24;57(8):3484-93.